Martínez GK, Díaz SJ

Idioma: Español
Referencias bibliográficas: 34
Paginas: 483-490
Archivo PDF: 284.42 Kb.

RESUMEN

La diabetes mellitus tipo 2 es una enfermedad crónica, degenerativa e, incurable pero controlable. La historia natural de su evolución trae como consecuencia que muchos pacientes evolucionen, inevitablemente a pesar del tratamiento. Las principales clases de antidiabéticos utilizados en monoterapia resultan, a largo plazo, en incremento glucémico progresivo. Para los pacientes que requieren una combinación de antidiabéticos orales existen, actualmente, varias combinaciones de dosis fijas. El uso de una combinación de dos o más agentes terapéuticos con mecanismos de acción complementarios permite optimizar el cumplimiento y el apego al tratamiento. La mayor reducción de HbA1c se observa con saxagliptina más metformina de liberación prolongada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;1047- 1053.

2. Villalpando S, De la Cruz V, Rojas R, Avila MA, Gaona B, Rebollar R, Hernández L. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica de Mexico 21010;52(1)

3. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249- 1258.

4. Kahn SE, Haffner SM, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.

5. Levy J, et al. Beta cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: 10 year follow up of the Belfast Diet Study. Diabet Med 1998;15:290-296.

6. Cook MN, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000.

7. Inzucchi S, et al. Management of Hyperglycemia in Type 2 Diabetes: A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1-16.

8. Benford M, et al. Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance. Adv Ther 2012;29(1):26-40.

9. Garber AJ, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-208.

10. Perez A., et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25:2915-2923.

11. Rosenstock J, et al. Initial treatment with rosiglitazone/ metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-660.

12. Goldstein BJ, et al. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890-903.

13. Moses R, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-124.

14. Goldstein BJ. Effect of initial combination therapy with sitagliptin, a dipeptidylpeptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.

15. Jadzinsky M, et al. Saxagliptin given in combination with metofrmin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.

16. Bosi E., Camisasca et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-895.

17. Goldstein BJ, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycaemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.

18. Scott LJ, et al. Linagliptina: in type 2 diabetes mellitus. Drugs 2011;71(5):611-24.

19. Bristol Myers Squibb-AstraZeneca EEIG. Onglyza (saxagliptin) 2.5, 5mg film-coated tablets: summary of product characteristics. Disponible en: URL:http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR__Product information/ human/001039/WC500044316.pdf.

20. Hollander PA, et al. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122(3):71-80.

21. European Medicines Agency. CHMP assessment report for Onglyza. Disponible en: URL:http://www.ema.europa.eu/docs/ en_GB/document:library/EAPAR__Public_assessment_report/ human/001039/WC500044319.pdf

22. Natali A, et al. Vascular effects of improving metabolic control with metfrormin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27(6):1349-57.

23. Turner RC, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 1999;281(21):2005-12.

24. Gibaldi M, et al. Pharmacokinetics in clinical practice. I. concepts. JAMA 1976;235(17):1864-7.

25. Lowell BB, et al. Mitochondrial dysfunction and type 2 diabetes. Science 2005:307(5708):384-7.

26. Timmis P, et al. Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation. Clin Pharmacokinet 2005;44(7):721-729.

27. Hebden JM, et al. Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit forumulations. Eur J Gastroenterol Hepatol 1999;11:1379-85.

28. Glucophage (metformin hydrochloride) and glucophage XR (metformin hydrochloride extended-release tablets) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2002.

29. Boulton D, et al. Bioequivalence of saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects. Clin Drug Investig 2011;31(9):619-630.

30. Guillausseau PJ. Influence of oral antidiabtic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29(1):79-81.

31. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformininduced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122(2):112-20.

32. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformina in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010;2:1.

33. Blonde L, et al. Gastrointestinal tolerabililty of extended-release metformin tablets compared to inmmediate-release metformin tablets: results of retrospective cohort study. Current Medical Research and Opinion 2004;20(4):565-572.

34. Benford M., et al. Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance. Adv Ther 2012;29(1):26-40.